📊 BIOE Key Takeaways
Is Bio Essence Corp (BIOE) a Good Investment?
Bio Essence Corp exhibits severe financial distress with negative stockholders' equity of -$3.1M and deteriorating operational performance including 41.3% YoY revenue decline. The company faces imminent solvency risk with current ratio of 0.06x, indicating critical liquidity constraints and inability to meet near-term obligations. While positive operating cash flow provides temporary relief, the underlying business fundamentals are deeply challenged with negative operating margins of -31.0% and minimal cash reserves.
Bio Essence Corp shows severe financial distress despite a high reported gross margin and positive free cash flow. Revenue declined sharply, operations remain materially loss-making, and the balance sheet is deeply impaired with negative equity, minimal cash, and extremely weak liquidity. The positive operating cash flow appears low quality relative to ongoing losses and does not offset the company’s solvency risk.
Why Buy Bio Essence Corp Stock? BIOE Key Strengths
- Strong gross margin of 68.2% suggests viable product pricing
- Positive operating cash flow of $328.7K demonstrates some cash generation capability
- Free cash flow of $325.1K with 77.8% FCF margin shows non-cash charges may be inflating losses
- Gross margin remains relatively strong at 68.2%, indicating the core product mix can generate solid unit-level profitability
- Reported operating cash flow and free cash flow were positive in the latest period, which may provide short-term funding support
- Capital expenditure is very low, limiting near-term cash demands from investment spending
BIOE Stock Risks: Bio Essence Corp Investment Risks
- Negative stockholders' equity of -$3.1M indicates balance sheet insolvency and technical bankruptcy
- Severe liquidity crisis with current ratio of 0.06x and only $28.7K cash against $3.3M liabilities
- Revenue collapse of 41.3% YoY combined with negative operating margin of -31.0% signals business model failure
- Total liabilities of $3.3M exceed total assets of $184.5K by 17.9x, creating existential refinancing risk
- No insider support with zero Form 4 filings in last 90 days suggests management lack of confidence
- Revenue fell 41.3% year over year, raising concern about demand stability and business durability
- Operating and net margins are deeply negative, showing the company is not covering its overhead and financing burden
- Balance sheet risk is extreme, with negative stockholders equity, a 0.06x current ratio, and very low cash relative to liabilities
Key Metrics to Watch
- Quarterly revenue trend and path to profitability
- Stockholders' equity trajectory and capital restructuring plans
- Operating cash flow sustainability and working capital management
- Debt refinancing status and covenant compliance
- Revenue trend and operating margin improvement
- Cash balance, current liabilities, and operating cash flow quality
Bio Essence Corp (BIOE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 77.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
BIOE Profit Margin, ROE & Profitability Analysis
BIOE vs Healthcare Sector: How Bio Essence Corp Compares
How Bio Essence Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bio Essence Corp Stock Overvalued? BIOE Valuation Analysis 2026
Based on fundamental analysis, Bio Essence Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bio Essence Corp Balance Sheet: BIOE Debt, Cash & Liquidity
BIOE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bio Essence Corp's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
BIOE Revenue Growth, EPS Growth & YoY Performance
BIOE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $134.7K | $13.0K | N/A |
| Q2 2025 | $41.7K | $59.9K | $0.00 |
| Q1 2025 | $22.2K | $133.9K | $0.00 |
| Q3 2024 | $134.7K | $133.9K | $-0.01 |
| Q3 2023 | $155.7K | -$164.2K | $-0.01 |
| Q2 2023 | $259.6K | -$164.2K | $0.00 |
| Q1 2023 | $306.4K | -$178.8K | $-0.01 |
| Q3 2022 | $192.1K | -$163.5K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bio Essence Corp Dividends, Buybacks & Capital Allocation
BIOE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bio Essence Corp (CIK: 0001723059)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIOE
What is the AI rating for BIOE?
Bio Essence Corp (BIOE) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIOE's key strengths?
Claude: Strong gross margin of 68.2% suggests viable product pricing. Positive operating cash flow of $328.7K demonstrates some cash generation capability. ChatGPT: Gross margin remains relatively strong at 68.2%, indicating the core product mix can generate solid unit-level profitability. Reported operating cash flow and free cash flow were positive in the latest period, which may provide short-term funding support.
What are the risks of investing in BIOE?
Claude: Negative stockholders' equity of -$3.1M indicates balance sheet insolvency and technical bankruptcy. Severe liquidity crisis with current ratio of 0.06x and only $28.7K cash against $3.3M liabilities. ChatGPT: Revenue fell 41.3% year over year, raising concern about demand stability and business durability. Operating and net margins are deeply negative, showing the company is not covering its overhead and financing burden.
What is BIOE's revenue and growth?
Bio Essence Corp reported revenue of $418.1K.
Does BIOE pay dividends?
Bio Essence Corp does not currently pay dividends.
Where can I find BIOE SEC filings?
Official SEC filings for Bio Essence Corp (CIK: 0001723059) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIOE's EPS?
Bio Essence Corp has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BIOE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bio Essence Corp has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BIOE stock overvalued or undervalued?
Valuation metrics for BIOE: ROE of N/A (sector avg: 15%), net margin of -31.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BIOE stock in 2026?
Our dual AI analysis gives Bio Essence Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BIOE's free cash flow?
Bio Essence Corp's operating cash flow is $328.7K, with capital expenditures of $3.6K. FCF margin is 77.8%.
How does BIOE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -31.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.06 (avg: 2).